[FG] Hartmann Karin

Research Focus

Immunology & Infectious Diseases

Area of Research

The aim of our research is to provide optimal care for patients with mast cell-associated diseases such as mastocytosis, urticaria and atopic dermatitis. Mast cells are important effector cells in allergies and regulate immunological processes in inflammatory diseases, autoimmune diseases and tumors. Pathologic mast cell proliferation is seen in diverse conditions including mastocytosis, urticaria and atopic dermatitis. We investigate their pathogenesis and develop new diagnostic and therapeutic options for these diseases.

Ongoing Research Projects

Mastocytosis

• APEX

A phase 2 open-label, multicenter clinical study of the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib as a single agent in patients with advanced systemic mastocytosis

• ECNM Registry

International registry for patients with mastocytosis

• HARBOR

A randomized, double-blind, placebo-controlled phase 2/3 study of elenestinib in indolent systemic mastocytosis

• SUMMIT

A multi-part, randomized, double-blind, placebo-controlled phase 2 clinical study of the safety and efficacy of bezuclastinib in subjects with nonadvanced systemic mastocytosis

• PIONEER

A 3-part, randomized, double-blind, placebo-controlled phase 2 study to evaluate safety and efficacy of Avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis

Anaphylaxis

• ANA/NORA Registry

International registry for patients with anaphylaxis

• EPAP

Prospective questionnaire study for patients with repeated anaphylactic reactions to food allergens

• POA Registry

Registry for patients with peri-operative anaphylaxis

Hereditary Angioedema

• APeX-N

Non-interventional post-authorisation study to evaluate the safety, tolerability, and effectiveness of berotralstat for patients with hereditary angioedema (HAE) in a real-world setting

Hereditary Alpha-Tryptasemia

• HαT Registry

Registry for patients with hereditary alpha-tryptasemia

Atopic Dermatitis

• TREATswitzerland

National registry for patients with moderate-to-severe atopic dermatitis on systemic therapy

• TRACE

An observational cohort study of atopic dermatitis patients prescribed tralokinumab

• ADhope 2

Phase 3b open-label study of lebrikizumab in patients with moderate-to-severe atopic dermatitis

• Teleallergology

Survey study to evaluate patients’ needs and expectations regarding telemedicine in allergology